Compare Yuwell CT3 to Other CGMs

We believe the Yuwell CT3 offers the strongest combination of accuracy, convenience and long-term value for Australians who are not eligible for NDSS subsidies.

Yuwell CT3 is factory-calibrated and does not require routine finger-prick calibration. Its registration clinical study showed a MARD of 9.07%, while the most recent independent published study reported 6.9% — both at or below the commonly accepted <10% benchmark for modern CGMs.

CareSens Air’s published clinical study reported a MARD of 10.42%. While the newer version makes calibration optional, any optional calibrations still require finger-prick testing with a blood glucose meter, adding ongoing cost and inconvenience that many users prefer to avoid.

FreeStyle Libre 2 Plus and Dexcom ONE+ are excellent systems, but their fully disposable designs typically result in higher long-term ownership costs. Both Ottai and Yuwell CT3 are ARTG-listed.

With a reusable transmitter, 14-day wear, no routine calibration, strong independent accuracy data and ARTG listing, the Yuwell CT3 delivers premium performance at a lower long-term cost.

MARD (Mean Absolute Relative Difference) is the standard measure of CGM accuracy. It shows the average percentage difference between the sensor’s glucose readings and a reference blood glucose measurement.

The lower the MARD, the closer the sensor readings are to the reference values.

In clinical practice, MARD values below 10% are generally regarded as high accuracy and are typical of modern CGM systems. Leading systems commonly report overall MARDs in the 8–9% range.

Published figures

• Yuwell CT3: 9.07% (registration study) and 6.9% (latest independent clinical study)
• CareSens Air: 10.42% (published clinical study)

Yuwell’s published results sit at or below the widely referenced <10% benchmark, while CareSens Air’s primary published figure sits above it.

Key sources

• Yuwell CT3 registration study: MARD 9.07%
• Yuwell CT3 latest study: Lancaster et al., British Journal of Nursing 2026 – MARD 6.9% (PubMed 41706553)
• CareSens Air: Kim et al., Diabetes Technology & Therapeutics 2024 – MARD 10.42%
• FreeStyle Libre 2 Plus: Clinical study data – MARD 8.2%
• ARTG: https://www.tga.gov.au/
• NDSS: https://www.ndss.com.au/

Disclaimer
Annual cost figures are estimates only. Optional calibrations incur extra costs for test strips and lancets. Real-world Bluetooth range is often less than the stated maximum. Always follow the current Australian Instructions for Use and consult a healthcare professional. Product features and regulatory status can change.

• Always read the label and follow the instructions for use provided with the Yuwell CT3 CGM system. This product is a medical device intended for monitoring interstitial glucose levels in people with diabetes. It is not a substitutae for professional medical advice, diagnosis, or treatment.
• Consult your healthcare professional (e.g., doctor, diabetes educator, or endocrinologist) before starting or changing your diabetes management plan, including the use of any CGM device, insulin dosing decisions, or interpretation of glucose data.
• The Yuwell CT3 CGM provides glucose readings every 3 minutes via interstitial fluid and is approved for non-adjunctive use in making diabetes treatment decisions where indicated in the instructions for use. However, in certain situations (e.g., rapidly changing glucose levels, suspected inaccuracy, symptoms not matching readings, or when alerts are not active), confirmatory finger-prick blood glucose testing with a blood glucose meter may be required.
• Accuracy (MARD) values are based on manufacturer clinical studies and may vary by individual, study population, and conditions. All CGM devices have limitations, including potential for compression lows, signal loss, interference from substances (e.g., acetaminophen/paracetamol in high doses for some systems), skin irritation, or adhesive issues.
• Pricing and Costs: All prices shown are indicative private retail/subscription costs as of February 2026 and exclude shipping, taxes, or promotions. The Yuwell CT3 subscription is $96/month(includes 2 sensors for ~continuous 14-day coverage). Actual costs may vary. NDSS subsidies significantly reduce costs for eligible Australians (often to $0–$17.35 per sensor or equivalent co-pay for Type 1 diabetes and certain other conditions). Check current NDSS eligibility, application process, and approved suppliers at ndss.com.au or call the NDSS Helpline on 1800 637 700. Yuwell CT3 availability and subsidy status should be confirmed directly with your healthcare provider or the sponsor/distributor (Revelare DX Pty Ltd).
• Annual costs are approximate and may vary depending on actual wear duration, sensor life achieved, subscription models and individual purchasing patterns. Optional calibrations (CareSens Air) incur additional ongoing costs for blood glucose test strips and lancets.
• Comparisons (e.g., features, waterproof ratings, accuracy, costs) are based on publicly available manufacturer data, TGA ARTG listings, clinical studies, and distributor information at the time of publication. Devices may differ in real-world performance, user experience, app compatibility (iOS/Android), and features like alerts, sharing, or integrations. Not all devices are subsidised equally via NDSS.
• Water resistance ratings (e.g., IP58 for Yuwell CT3) indicate protection under specified test conditions (e.g., 1.5 m depth for 2 hours) but are not guarantees for all scenarios (e.g., high-pressure water, hot tubs, seawater, prolonged exposure, or damage over time). Follow manufacturer guidelines for water exposure, drying, and adhesive care.
• This website does not provide medical advice. Information is for educational and comparison purposes only. Product availability, specifications, and pricing may change. The sponsor (Revelare DX Pty Ltd) and any associated entities are not responsible for decisions made based solely on this content.
• For adverse events, product issues, or complaints, contact the manufacturer/sponsor or report to the Therapeutic Goods Administration (TGA) at tga.gov.au.